QCOR Related Analyst Ratings
-
Favus Institutional Research Downgrades Questcor Pharmaceuticals (QCOR) to Sell
-
Janney Montgomery Scott Starts Questcor Pharmaceuticals (QCOR) at Buy
-
Mizuho Securities Upgrades Questcor Pharmaceuticals (QCOR) to Buy
-
Mizuho Securities Starts Questcor Pharmaceuticals (QCOR) at Neutral
-
Questcor (QCOR) Higher on Positive Physician Feedback
-
Ladenburg Thalmann Upgrades Questcor Pharmaceuticals (QCOR) to Buy
-
Leerink Trims Valuation Range on Questcor (QCOR); Still Sees Broader Acthar Risk
-
Questcor (QCOR) Higher as Analyst Sees Continued Acthar Coverage Based on Efficacy
-
Jefferies Upgrades Questcor Pharmaceuticals (QCOR) to Buy, Sees Little Downside and Improved Visibility
-
Oppenheimer Sees Upside in Shares of Jazz Pharmaceuticals (JAZZ)
-
Oppenheimer Downgrades Questcor Pharmaceuticals (QCOR) to Perform after Probe
-
Piper Jaffray Downgrades Questcor Pharmaceuticals (QCOR) to Neutral
-
Leerink Swann Drops Questcor (QCOR) to Market Perform; Cites Broader Acthar Risk
-
Leerink Swann Would Buy Questcor (QCOR) on Weakness, Drug Remains Available to Patients
-
Oppenheimer Defends Questcor (QCOR) on Acthar Concerns; Says Sell-Off Overdone
-
Jefferies Downgrades Questcor Pharmaceuticals (QCOR) to Hold, Cuts Target in Half
-
Questcor Pharmacueticals (QCOR) Slammed 34% On Reports Aetna Insurance Coverage Dropped
-
Oppenheimer Lifts Target on Questcor (QCOR) After Investor Meetings
-
Jefferies Highights Incremental Positive Feedback on Questcor's (QCOR) Acthar at Meeting
-
Leerink Swann Lifts Valuation Range on Questcor (QCOR) Following Acthar Medicaid Update
-
BofA/Merrill Lynch added Questcor Pharmaceuticals (QCOR) to its Focus 1 List
-
Questcor (QCOR) Sees Upside on Positive Comments on Generic Acthar
-
SunTrust Robinson Humphrey Upgrades Questcor Pharmaceuticals (QCOR) to Buy
-
Oppenheimer Maintains an 'Outperform' on Questcor Pharma (QCOR); Bringing In The Consultant
-
Leerink Swann Maintains Bullish View on Questcor (QCOR) After Results
-
Leerink Swann Starts Questcor Pharmaceuticals (QCOR) at Outperform; Expecting Meaningful Acthar Growth
-
BofA/Merrill Lynch Starts Questcor Pharmaceuticals (QCOR) at Buy
-
Analysts Dismiss Negative Reports on Questcor (QCOR) as "Misleading"
-
Analysts Defend Questcor (QCOR) On Free-Fall In Shares
-
Questcor (QCOR) Taps News Highs on Strong June Acthar Sales; Jefferies Boosts Target
-
Oppenheimer Reiterates an 'Outperform' on Questcor Pharmaceuticals (QCOR); Expansion Strategy Into Rheumatology
-
Jefferies Boosts Numbers on Questcor (QCOR) After Including Acthar DM/PM Sales in Model
-
Jefferies Maintains Bullish Stance On Questcor (QCOR) Following Meeting
-
Jefferies Raises Questcor Pharmaceuticals (QCOR) Price Target From $50 to $52
-
Piper Jaffray Starts Questcor Pharmaceuticals (QCOR) at Overweight
-
Piper Jaffray Starts Questcor Pharmaceuticals (QCOR) at Overweight
-
Roth Capital Starts Questcor Pharmaceuticals (QCOR) at Buy
-
Oppenheimer Reiterates Bullish View on Questcor Pharmaceuticals (QCOR) After Nephrologists Conversations
-
Oppenheimer Maintains an 'Outperform' on Questcor Pharmaceuticals (QCOR); Share Buyback A Positive
-
Jefferies Positive On Questcor Pharmaceuticals (QCOR) Following Q4 Results, Dispels Negative Rumors
-
Analysts Not Impressed with StreetSweeper Article on Questcor (QCOR)
-
Questcor (QCOR) Jumps Higher, Jefferies Says Allegations Much Ado About Nothing
-
Oppenheimer Recommends Buying Questcor (QCOR) On Weakness
-
Questcor (QCOR) Defended at Jefferies
-
WJB Capital Starts Questcor Pharmaceuticals (QCOR) at Buy
-
Leerink Swann Starts Questcor Pharmaceuticals (QCOR) at Outperform; Momentum Trumps Multiple
-
Ladenburg Thalmann Starts Questcor Pharmaceuticals (QCOR) at Buy
-
Jefferies maintains a 'Buy' on Questcor Pharmaceuticals (QCOR); Strong 2011 Execution Should Continue In 2012
-
Jefferies Raises Price Target on Questcor Pharmaceuticals (QCOR) to Reflect New Estimates
-
ThinkEquity Starts Questcor Pharmaceuticals (QCOR) at Buy
Back to QCOR Stock Lookup
